Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.

PubWeight™: 7.09‹?› | Rank: Top 1%

🔗 View Article (PMID 12097271)

Published in Cancer Res on July 01, 2002

Authors

Montserrat Sanchez-Cespedes1, Paola Parrella, Manel Esteller, Shuji Nomoto, Barry Trink, James M Engles, William H Westra, James G Herman, David Sidransky

Author Affiliations

1: Department of Otolaryngology-Head and Neck Surgery, Head and Neck Cancer Research Division, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-2196, USA. msanchez@cnio.es

Articles citing this

(truncated to the top 100)

Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41

A census of human cancer genes. Nat Rev Cancer (2004) 36.20

Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02

AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell (2008) 16.72

Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69

Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02

The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer (2009) 8.43

AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev (2011) 5.26

AMP-activated protein kinase--development of the energy sensor concept. J Physiol (2006) 4.93

LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell (2013) 4.58

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther (2006) 4.09

Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell (2009) 3.85

Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature (2013) 3.76

Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell (2010) 3.40

LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) (2009) 2.94

NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene (2010) 2.56

Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther (2009) 2.47

Retracted LKB1 and AMPK maintain epithelial cell polarity under energetic stress. J Cell Biol (2007) 2.40

Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene (2007) 2.27

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer (2008) 2.21

AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol (2010) 2.11

Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal (2009) 2.11

mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci U S A (2009) 2.08

Degradation of AMPK by a cancer-specific ubiquitin ligase. Cell (2015) 1.91

Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther (2011) 1.74

LKB1 and AMPK and the cancer-metabolism link - ten years after. BMC Biol (2013) 1.73

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol (2009) 1.70

Molecular biology of lung cancer. J Thorac Dis (2013) 1.67

Potential applications for biguanides in oncology. J Clin Invest (2013) 1.63

AMP-activated protein kinase regulates CO2-induced alveolar epithelial dysfunction in rats and human cells by promoting Na,K-ATPase endocytosis. J Clin Invest (2008) 1.58

Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res (2012) 1.47

Molecular biology of lung cancer: clinical implications. Clin Chest Med (2011) 1.47

Genome-wide RNAi screen reveals disease-associated genes that are common to Hedgehog and Wnt signaling. Sci Signal (2011) 1.45

Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing. PLoS One (2016) 1.43

LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis. Cancer Res (2008) 1.42

LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc Natl Acad Sci U S A (2010) 1.40

Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol (2010) 1.36

SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal (2009) 1.35

LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br J Cancer (2009) 1.33

Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? Lung Cancer (2010) 1.30

Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis (2008) 1.29

LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. Cancer Res (2008) 1.28

Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov (2013) 1.27

Reactive nitrogen species is required for the activation of the AMP-activated protein kinase by statin in vivo. J Biol Chem (2008) 1.26

Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas. Cancer Res (2010) 1.23

Systematic analysis of genetic alterations in tumors using Cancer Genome WorkBench (CGWB). Genome Res (2007) 1.22

Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci U S A (2011) 1.21

Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. Oncogene (2011) 1.21

Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells. Cancer Res (2008) 1.20

Molecular pathways and therapeutic targets in lung cancer. Oncotarget (2014) 1.16

Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α. Proc Natl Acad Sci U S A (2014) 1.14

Role of LKB1 in lung cancer development. Br J Cancer (2008) 1.14

Enhancing mTOR-targeted cancer therapy. Expert Opin Ther Targets (2009) 1.13

Mapping tumor-suppressor genes with multipoint statistics from copy-number-variation data. Am J Hum Genet (2006) 1.13

Cancer genes in lung cancer: racial disparities: are there any? Genes Cancer (2012) 1.12

Summary of the proceedings from the 10th annual meeting of molecularly targeted therapy in non-small cell lung cancer. J Thorac Oncol (2010) 1.11

Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy. Curr Genomics (2009) 1.11

Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas. J Thorac Oncol (2010) 1.10

Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy. Front Oncol (2013) 1.08

Phosphorylation by Akt within the ST loop of AMPK-α1 down-regulates its activation in tumour cells. Biochem J (2014) 1.07

LKB1, the multitasking tumour suppressor kinase. J Clin Pathol (2005) 1.07

The role of LKB1 in lung cancer. Fam Cancer (2011) 1.07

The genomics of lung adenocarcinoma: opportunities for targeted therapies. Genes Cancer (2010) 1.05

The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila) (2011) 1.02

LKB1 catalytic activity contributes to estrogen receptor alpha signaling. Mol Biol Cell (2009) 1.00

The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol (2011) 1.00

LKB1 regulated pathways in lung cancer invasion and metastasis. J Thorac Oncol (2010) 0.99

AMP-activated protein kinase suppresses the in vitro and in vivo proliferation of hepatocellular carcinoma. PLoS One (2014) 0.98

Aberrant transcriptional regulations in cancers: genome, transcriptome and epigenome analysis of lung adenocarcinoma cell lines. Nucleic Acids Res (2014) 0.98

Homozygous deletion of the STK11/LKB1 locus and the generation of novel fusion transcripts in cervical cancer cells. Cancer Genet Cytogenet (2010) 0.97

LKB1 loss in melanoma disrupts directional migration toward extracellular matrix cues. J Cell Biol (2014) 0.97

Recent progress on liver kinase B1 (LKB1): expression, regulation, downstream signaling and cancer suppressive function. Int J Mol Sci (2014) 0.96

Investigation of LKB1 Ser431 phosphorylation and Cys433 farnesylation using mouse knockin analysis reveals an unexpected role of prenylation in regulating AMPK activity. Biochem J (2014) 0.96

FOXO3 is a glucocorticoid receptor target and regulates LKB1 and its own expression based on cellular AMP levels via a positive autoregulatory loop. PLoS One (2012) 0.95

Cell-type-dependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia. Mol Cell Biol (2011) 0.95

Gene expression of the tumour suppressor LKB1 is mediated by Sp1, NF-Y and FOXO transcription factors. PLoS One (2012) 0.94

Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma. Lung Cancer (2014) 0.93

LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT. J Thorac Oncol (2014) 0.92

LKB1 represses focal adhesion kinase (FAK) signaling via a FAK-LKB1 complex to regulate FAK site maturation and directional persistence. J Biol Chem (2013) 0.92

Restoration of silenced Peutz-Jeghers syndrome gene, LKB1, induces apoptosis in pancreatic carcinoma cells. Neoplasia (2003) 0.92

The CRTC1-NEDD9 signaling axis mediates lung cancer progression caused by LKB1 loss. Cancer Res (2012) 0.91

Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer. Neoplasia (2011) 0.90

Liver kinase B1 (LKB1) in the pathogenesis of epithelial cancers. Cancer Lett (2011) 0.90

cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth. J Clin Invest (2016) 0.89

Mining the epigenome for methylated genes in lung cancer. Proc Am Thorac Soc (2008) 0.89

ATM and LKB1 dependent activation of AMPK sensitizes cancer cells to etoposide-induced apoptosis. Cancer Lett (2012) 0.89

Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer. Transl Lung Cancer Res (2015) 0.89

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene (2015) 0.89

Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. Pharmgenomics Pers Med (2015) 0.88

LKB1 Tumor Suppressor: Therapeutic Opportunities Knock when LKB1 Is Inactivated. Genes Dis (2014) 0.87

Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells. Acta Pharmacol Sin (2012) 0.87

Molecular Pathways: Is AMPK a Friend or a Foe in Cancer? Clin Cancer Res (2015) 0.87

Targeting the LKB1 tumor suppressor. Curr Drug Targets (2014) 0.87

CDKN2A/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer. J Thorac Oncol (2013) 0.86

LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells. Oncogene (2015) 0.85

LKB1 signaling in advancing cell differentiation. Fam Cancer (2011) 0.85

A novel mutation of STK11/LKB1 gene leads to the loss of cell growth inhibition in head and neck squamous cell carcinoma. Oncogene (2006) 0.85

Breaking the epithelial polarity barrier in cancer: the strange case of LKB1/PAR-4. Philos Trans R Soc Lond B Biol Sci (2013) 0.85

PARD3 Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion. Cancer Res (2015) 0.84

Articles by these authors

Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74

Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12

Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A (2005) 15.46

The Polycomb group protein EZH2 directly controls DNA methylation. Nature (2005) 13.67

Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst (2008) 12.77

Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12

A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45

Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78

Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics (2011) 7.38

Epigenetic modifications and human disease. Nat Biotechnol (2010) 7.29

A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14

HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol (2010) 6.53

The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci (2003) 6.24

BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst (2003) 6.20

TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med (2007) 5.92

DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med (2008) 5.87

Cancer epigenetics reaches mainstream oncology. Nat Med (2011) 5.83

Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med (2006) 5.80

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64

Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res (2007) 5.62

A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet (2002) 5.38

Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 4.60

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39

DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nat Cell Biol (2006) 4.38

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol (2008) 4.32

A role for RNAi in the selective correction of DNA methylation defects. Science (2009) 4.30

Distinct DNA methylomes of newborns and centenarians. Proc Natl Acad Sci U S A (2012) 4.26

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res (2006) 4.15

Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol (2004) 4.15

Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med (2005) 4.12

Retracted A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet (2009) 3.88

Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res (2009) 3.81

Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation. Nat Genet (2005) 3.66

Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol (2008) 3.60

Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet (2006) 3.54

DNA methylation and cancer. Adv Genet (2010) 3.50

Epigenetics and aging: the targets and the marks. Trends Genet (2007) 3.44

Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res (2003) 3.42

Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood (2009) 3.35

DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet (2012) 3.33

BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24

Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell (2002) 3.12

Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res (2006) 3.05

Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol (2009) 3.05

Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol (2012) 3.04

Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol (2002) 3.00

Intense (18)F-FDG uptake in brown fat can be reduced pharmacologically. J Nucl Med (2004) 3.00

Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology (2008) 2.91

Low-level microsatellite instability in most colorectal carcinomas. Cancer Res (2002) 2.87

Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell (2010) 2.86

PcG proteins, DNA methylation, and gene repression by chromatin looping. PLoS Biol (2008) 2.85

Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res (2002) 2.84

Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res (2004) 2.84

Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81

A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell (2010) 2.78

A systematic profile of DNA methylation in human cancer cell lines. Cancer Res (2003) 2.75

A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther (2011) 2.74

DNA methylation: a profile of methods and applications. Biotechniques (2002) 2.74

The role of histone deacetylases (HDACs) in human cancer. Mol Oncol (2007) 2.72

Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer (2010) 2.69

Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res (2008) 2.66

MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer (2008) 2.56

The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res (2004) 2.54

p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst (2003) 2.54

Notch signaling is essential for ventricular chamber development. Dev Cell (2007) 2.53

Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol (2012) 2.53

DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res (2003) 2.46

Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer. Surgery (2013) 2.43

Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol (2003) 2.42

GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol (2003) 2.42

The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic Acids Res (2003) 2.41

Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41

Allele-specific histone lysine methylation marks regulatory regions at imprinted mouse genes. EMBO J (2002) 2.40

DNA methylation markers in colorectal cancer. Cancer Metastasis Rev (2010) 2.40

Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst (2002) 2.38

Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell (2003) 2.38

SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood (2002) 2.34

Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res (2004) 2.34

A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet (2006) 2.33

Ectopic expression of the sodium-iodide symporter enables imaging of transplanted cardiac stem cells in vivo by single-photon emission computed tomography or positron emission tomography. J Am Coll Cardiol (2008) 2.33

Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res (2005) 2.32

Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31

Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res (2003) 2.28